These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


296 related items for PubMed ID: 27418178

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting.
    Santoro A, Fontana A, Miscio AM, Zarrelli MM, Copetti M, Leone MA.
    Neurol Sci; 2017 Oct; 38(10):1779-1789. PubMed ID: 28726049
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 7. The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis.
    Matharu M, Halker R, Pozo-Rosich P, DeGryse R, Manack Adams A, Aurora SK.
    J Headache Pain; 2017 Dec; 18(1):78. PubMed ID: 28766236
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC.
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Botulinum toxin A in chronic refractory migraine: premarketing experience].
    Álvaro-González LC, Fernández-García JM, Aranzábal-Alustiza I, Castillo-Calvo B, Iriondo-Etxenagusia I, Rodríguez-Antigüedad A.
    Rev Neurol; 2012 Oct 01; 55(7):385-91. PubMed ID: 23011856
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
    Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW.
    J Neurol Sci; 2013 Aug 15; 331(1-2):48-56. PubMed ID: 23790235
    [Abstract] [Full Text] [Related]

  • 15. Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: An open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety.
    Boudreau GP, Grosberg BM, McAllister PJ, Lipton RB, Buse DC.
    Int J Gen Med; 2015 Aug 15; 8():79-86. PubMed ID: 25733924
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention.
    Lipton RB, Silberstein SD.
    Headache; 2015 Mar 15; 55 Suppl 2():103-22; quiz 123-6. PubMed ID: 25662743
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 15.